PCOS and Fertility: Why Ovulation Stalls and the Step-by-Step Options

Scroll through any parenting forum this month and the same three words keep surfacing: letrozole, inositol and “Ozempic babies.” Search interest in pcos and fertility has climbed sharply since the 2023 international PCOS guideline reshuffled the treatment ladder and the World Health Organization published its first dedicated fact sheet, estimating that up to 70 percent of people with the condition have never been diagnosed. As of early 2025, the conversation has moved from waiting rooms to short-form video, and not all of it survives contact with the evidence.

What the videos rarely show is the biology underneath: an ovary full of small follicles that keep starting and never finish. That stalled moment is the whole story of PCOS-related infertility, and it is more fixable than most people fear.

This explainer walks through why ovulation stalls, what each treatment step actually does, how strong the evidence is for each, and which viral claims deserve a polite correction.

What changed recently in PCOS and fertility care

Three developments explain the current surge of attention, and only one of them is a trial.

The first is a guideline. In 2023, the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome was updated by a consortium of professional societies across several continents. It recommended letrozole, a medicine originally developed for breast cancer, as the preferred first-line tablet for inducing ovulation, ahead of clomiphene, which had held that spot for sixty years. It also accepted a blood test for anti-Müllerian hormone (AMH, a hormone produced by small ovarian follicles) as an alternative to ultrasound when confirming the diagnosis in adults.

The second is a public-health milestone. On 28 June 2023 the World Health Organization released a stand-alone PCOS fact sheet. It put prevalence at 8–13 percent of women of reproductive age, called PCOS the leading cause of anovulatory infertility (infertility caused by cycles in which no egg is released), and estimated that up to 70 percent of affected women worldwide remain undiagnosed. Those numbers were widely shared and gave the condition a visibility it had not had before.

The third is cultural. Reports of unexpected pregnancies among people taking GLP-1 weight-loss medicines, nicknamed “Ozempic babies,” and a wave of videos promoting inositol supplements as a natural alternative to prescription treatment have pushed PCOS into mainstream feeds. Neither claim has been tested in a fertility trial, and the Common myths section below sorts what is plausible from what is proven.

Mainstream patient resources from the NHS, Mayo Clinic and Cleveland Clinic have all been refreshed to reflect the letrozole shift, which is why the treatment ladder you read today looks different from the one your mother, or even your older sister, may have been offered.

Why ovulation stalls in PCOS: the mechanism in plain language

A normal cycle is a relay race. Follicle-stimulating hormone (FSH) from the pituitary gland recruits a handful of small follicles, one grows to roughly two centimeters and becomes dominant, and a surge of luteinizing hormone (LH) triggers it to release an egg. In PCOS, the baton is dropped early.

Four things go wrong at once. Androgens, the hormones often called “male” though every body makes them, run higher than usual inside the ovary. Insulin resistance, a state in which cells respond sluggishly to insulin so the pancreas pumps out more, pushes the ovary to produce still more androgen and lowers sex hormone-binding globulin, the protein that mops up free testosterone. The pituitary releases LH in rapid pulses relative to FSH, which favors androgen production over follicle growth. And AMH levels, typically two to three times higher than average, blunt the follicles’ response to the FSH that is available.

The result is an ovary holding many follicles stuck at two to nine millimeters, none of which reaches dominance. With no dominant follicle there is no estrogen peak, no LH surge and no egg. The “cysts” that give the syndrome its name are these arrested follicles, not fluid-filled growths that need removing.

There is a second consequence worth knowing. When ovulation does not happen, the uterine lining is bathed in estrogen without the progesterone that follows egg release. Over months this can produce unpredictable, sometimes heavy bleeding and, over years, raises the risk of abnormal thickening of the lining. Restoring regular ovulation, whether for conception or not, protects the uterus as well.

How PCOS is diagnosed when fertility is the question

There is no single PCOS test. Clinicians use the Rotterdam criteria, which require two of three features once other causes have been ruled out:

• Irregular or absent ovulation, usually seen as cycles longer than 35 days, fewer than eight or nine periods a year, or no periods at all.
• Evidence of excess androgen, either on examination (coarse facial or body hair, persistent acne, scalp hair thinning) or on a blood test showing elevated testosterone or related hormones.
• Polycystic ovarian morphology on ultrasound, meaning an increased follicle count or ovarian volume, or, in adults, an elevated AMH level in place of the scan.

Before applying those criteria, a doctor checks thyroid function, prolactin (a pituitary hormone that can suppress ovulation when high) and, in some cases, adrenal hormones, because these conditions can mimic PCOS and are treated differently.

Because the criteria allow several combinations, PCOS comes in four phenotypes. Someone with excess androgen and polycystic ovaries but regular cycles has a milder reproductive picture than someone with no periods and high testosterone. The phenotype matters for fertility planning, which is why it is worth asking which one applies to you.

One point is easy to miss in the rush toward treatment. A PCOS diagnosis does not exempt a couple from the other causes of infertility. Mainstream guidance is clear that a semen analysis for the male partner and, where indicated, a test of whether the fallopian tubes are open should be done before months are spent on ovulation induction. Roughly a third of infertility involves a male factor, and finding it late is a common, avoidable heartbreak.

PCOS pregnancy chances: what the numbers actually show

Start with the reassuring headline, because it is true: the NHS states that most women with PCOS are able to get pregnant with treatment, and large cohort studies find that family size by the end of the reproductive years is similar to that of women without the condition.

The more useful question is how quickly. In the largest head-to-head trial of first-line tablets, published in the New England Journal of Medicine in 2014 and involving 750 women with PCOS, cumulative ovulation across the treatment period was 61.7 percent with letrozole and 48.3 percent with clomiphene, and live birth rates were 27.5 percent versus 19.1 percent. Those figures sound modest until you remember that a healthy couple without fertility problems has roughly a one-in-five chance of conceiving in any given month. Treated PCOS, in other words, moves people back toward ordinary odds rather than guaranteeing a quick result.

Age still applies. Egg quality declines through the thirties for everyone, and PCOS does not pause that clock, although the higher follicle count means ovarian reserve is rarely the limiting factor. What PCOS does change is the timeline for seeking help: because cycles are irregular, waiting the conventional 12 months of “trying” may mean only four or five real opportunities to conceive. Guidelines therefore encourage earlier assessment.

Weight is a modifier, not a verdict. Observational data link higher body mass index (BMI, a weight-to-height ratio) with lower response to ovulation-inducing medicines, but a substantial share of people with PCOS are in the normal weight range and respond well. Numbers from population studies describe groups; your own chances depend on phenotype, age, partner factors and the step you are on.

How to get pregnant with PCOS: the step-by-step ladder at a glance

Ovulation induction is the medical term for coaxing the ovary to release an egg, and in PCOS it follows a ladder that guidelines agree on remarkably closely. Each rung is tried for a limited time before moving up, and a specialist may skip rungs depending on age, phenotype and other fertility factors.

Step	Option	What it does	Evidence strength
0	Preconception assessment	Confirms diagnosis, checks partner and tubes, optimizes health	Expert consensus
1	Lifestyle change	Improves insulin sensitivity; may restore ovulation in those with higher BMI	Moderate (small trials, observational data)
2	Letrozole	Lowers estrogen briefly so the brain releases more FSH	High (large randomized trial, meta-analyses)
2 alt.	Clomiphene, with or without metformin	Blocks estrogen feedback; metformin improves insulin action	High for clomiphene; moderate for the combination
3	Injectable gonadotropins	Supplies FSH directly under ultrasound monitoring	High, with higher multiple-pregnancy risk
3 alt.	Laparoscopic ovarian drilling	Keyhole surgery that lowers ovarian androgen output	Moderate (randomized trials versus gonadotropins)
4	IVF, often with freeze-all	Retrieves eggs, fertilizes them in the lab, transfers embryos later	High, including a large PCOS-specific trial

The order reflects a trade-off that runs through every step: effectiveness rises as you climb, but so do monitoring needs, the chance of twins or triplets, and the risk of ovarian hyperstimulation syndrome (OHSS), a condition in which over-stimulated ovaries swell and leak fluid into the abdomen.

Two caveats keep the table honest. First, “natural” and “medical” are not opposing camps; lifestyle work continues on every rung. Second, the ladder is a map, not a prescription. Which rung you start on, how long you stay and when you move belong to a conversation with the clinician who knows your history.

Step one: lifestyle, weight and what the evidence can and cannot promise

Lifestyle sits at the base of the ladder for a specific physiological reason, not a moral one. Insulin resistance drives ovarian androgen production, and anything that improves insulin sensitivity, whether aerobic exercise, resistance training, better sleep or modest weight loss, can lower androgens enough for a follicle to break through.

The evidence is moderate rather than overwhelming. Small randomized trials and larger observational studies suggest that in people with PCOS and a BMI in the overweight or obese range, losing around 5–10 percent of body weight restores regular ovulation in a meaningful minority and improves response to subsequent medicines. The 2023 guideline recommends lifestyle intervention as the first step for this group and specifically notes that no single diet, whether low-carbohydrate, Mediterranean or intermittent fasting, has proven superior for fertility outcomes. The best eating pattern is the one a person can sustain.

Two limits matter. Roughly a third to a half of people with PCOS are not overweight, and for them weight loss is neither necessary nor helpful; the phrase “lean PCOS” exists for a reason, and being told to lose weight when none needs losing is a common source of frustration. And for those who do carry extra weight, time is a cost. Spending a year on lifestyle change alone at 37 may not be the right trade, which is why guidelines pair lifestyle work with a clear time limit before moving to step two.

Preconception basics apply to everyone on this rung: a folic acid supplement as your clinician recommends, stopping smoking, limiting alcohol, reviewing any current medicines for pregnancy safety, and checking that routine vaccinations are up to date. Harvard Health and the NHS both frame these as the quiet, high-yield parts of trying to conceive, with or without PCOS.

Letrozole for PCOS: why it moved to first line

Letrozole is an aromatase inhibitor, meaning it blocks the enzyme that converts androgens into estrogen. Taken early in a cycle, it drops estrogen for a few days; the brain reads the drop as a signal that no follicle is growing and releases more FSH, and a follicle responds. Because letrozole clears the body quickly, estrogen production resumes normally once a follicle is on its way, so the uterine lining and cervical mucus develop as they should.

That last point is the practical difference from clomiphene, which lingers for weeks and blocks estrogen receptors in the uterus and cervix even as it stimulates the ovary. It is also the likely reason letrozole produced more live births in the 750-woman randomized trial described earlier, despite the two medicines inducing ovulation in broadly similar ways. Letrozole also tends to produce one dominant follicle rather than several, and in that trial the twin rate was 3.4 percent compared with 7.4 percent for clomiphene. Cochrane meta-analyses pooling more than 40 trials point the same way, so the evidence grade here is high.

Regulatory status deserves a plain statement. In the United States and many other countries letrozole is approved for breast cancer and its use for ovulation induction is off-label. The 2023 international guideline, the NHS and the Mayo Clinic nonetheless describe it as the preferred first-line option because of the trial data. An early worry about birth defects, raised in a 2005 conference abstract, was not supported by the larger studies that followed.

None of this is a reason to seek letrozole on your own. Whether it is appropriate, how it is monitored and when to move on are decisions for the prescribing clinician, who will weigh your phenotype, age and the rest of your fertility work-up.

Clomiphene and metformin: where they still fit

Clomiphene, sold for decades under the brand name Clomid, is a selective estrogen receptor modulator. It sits on estrogen receptors in the brain and blocks the signal that estrogen is present, so the pituitary releases more FSH. It remains widely used, is approved for ovulation induction, and works: around three-quarters of women with PCOS ovulate on it. Pregnancy rates lag behind ovulation rates, partly because of the anti-estrogen effects on the lining described above, and roughly 15–25 percent of women are “clomiphene-resistant,” meaning they do not ovulate at all. The multiple-pregnancy rate of about 7–8 percent is the other reason it has slipped to second choice.

Metformin is a type 2 diabetes medicine that reduces glucose output by the liver and improves how cells respond to insulin. In PCOS it lowers androgen levels modestly and can restore ovulation in some people when taken alone, but systematic reviews find its effect on live birth as a solo fertility treatment to be small and uncertain. Where the evidence is stronger is in combination: adding metformin to clomiphene in women who have not responded to clomiphene alone improves ovulation and clinical pregnancy rates, a finding graded moderate in guidelines. Digestive side effects such as nausea and loose stools are common early and usually settle.

Like letrozole, metformin’s use in PCOS is off-label in the United States, though it has been studied in this setting for 30 years and is endorsed by international guidelines for specific situations, particularly in people with glucose intolerance or higher BMI.

Which combination, if any, suits you is a clinical judgment. Neither medicine should be started, stopped or swapped without the prescribing doctor, and anyone already taking metformin for another reason should not assume it doubles as fertility treatment.

PCOS ovulation induction, step three: gonadotropins and ovarian drilling

When tablets fail, two routes open, and randomized trials suggest they reach similar destinations by different roads.

Gonadotropins are injectable medicines containing FSH, sometimes with LH, that stimulate the ovary directly rather than nudging the brain. They are highly effective at producing a follicle, which is precisely the problem in PCOS: an ovary full of waiting follicles can respond to FSH all at once. Specialists therefore use cautious, slowly adjusted protocols with regular ultrasound and blood monitoring, and will cancel a cycle if too many follicles develop. Even so, the multiple-pregnancy rate is higher than with tablets, and OHSS, the fluid-shift complication described earlier, becomes a real possibility. The evidence for gonadotropins is high quality; the price is intensity of monitoring.

Laparoscopic ovarian drilling takes the opposite approach. Under general anesthesia, a surgeon makes a handful of tiny punctures in each ovary using heat or laser through keyhole incisions. The procedure reduces the ovary’s androgen-producing tissue, and for reasons still not fully understood, around half of women resume spontaneous ovulation afterward, sometimes for years. Randomized trials comparing drilling with gonadotropins find comparable live birth rates with far fewer multiple pregnancies, which is why guidelines list it as a second-line alternative, particularly where close monitoring is impractical. The trade-offs are surgical risk, possible scar tissue around the ovaries and tubes, and a theoretical reduction in ovarian reserve if too much tissue is treated.

Both options are specialist territory. The choice between them depends on age, BMI, previous response, access to monitoring and personal preference about surgery versus injections, and it is made with, not for, the patient.

IVF for PCOS: the final step and the freeze-all strategy

In vitro fertilization retrieves eggs from the ovaries after stimulation, fertilizes them in the laboratory and transfers an embryo into the uterus. For PCOS it is the last rung, reserved for people who have not conceived with ovulation induction or who have an additional reason such as blocked tubes or a male factor.

PCOS brings a paradox to IVF. The same crowded ovary that stalls natural ovulation tends to yield many eggs under stimulation, so success rates per cycle are at least as good as for other causes of infertility. The hazard is OHSS, which is several times more likely in PCOS than in the general IVF population. Modern protocols reduce that risk through gentler stimulation, a different type of trigger injection and, increasingly, a decision not to transfer any embryo in the stimulated cycle.

That last approach, called freeze-all or elective frozen embryo transfer, has the strongest PCOS-specific evidence in the whole treatment ladder. A randomized trial of 1,508 women with PCOS published in 2016 found that freezing all embryos and transferring one in a later, unstimulated cycle produced a live birth rate of 49.3 percent compared with 42.0 percent for fresh transfer, with OHSS falling from 7.1 percent to 1.3 percent and pregnancy loss from 32.7 percent to 22.0 percent. The frozen group had a higher rate of preeclampsia (4.4 versus 1.4 percent), a finding that specialists now weigh when advising individuals.

In vitro maturation, in which immature eggs are collected with minimal stimulation and matured in the lab, is offered in some settings for PCOS and avoids OHSS almost entirely, but live birth data remain limited and it is best regarded as an emerging rather than established option.

What the evidence actually says, graded step by step

Not every claim about PCOS and fertility rests on the same foundation. Here is how the main options stack up, using the categories clinicians use: randomized controlled trials (RCTs, where participants are assigned by chance), observational studies (which follow people without assigning treatment) and expert opinion.

High-quality evidence. Letrozole producing more live births than clomiphene: a 750-woman RCT plus meta-analyses. Clomiphene inducing ovulation: decades of RCTs. Gonadotropins inducing ovulation: RCTs, with higher multiple-pregnancy risk. Freeze-all IVF in PCOS: a 1,508-woman RCT. Acupuncture not improving live birth in PCOS: a 1,000-woman sham-controlled RCT published in 2017.

Moderate-quality evidence. Lifestyle change restoring ovulation in people with higher BMI: small RCTs and consistent observational data, with no trial showing one diet beats another. Metformin added to clomiphene in clomiphene-resistant women: several RCTs with some inconsistency. Ovarian drilling matching gonadotropins for live birth: RCTs that are smaller and older.

Low or insufficient evidence. Inositol (myo- or D-chiro-inositol, sugar-like compounds involved in insulin signaling) for live birth: small, heterogeneous trials; the 2023 guideline concludes it may improve some metabolic markers but should not be considered a fertility treatment outside research. Vitamin D, berberine, cinnamon, omega-3 and “PCOS-friendly” elimination diets for conception: observational signals or tiny trials, no reliable live-birth data. GLP-1 receptor agonists (semaglutide, sold as Ozempic and Wegovy, and similar) for fertility: strong RCT evidence for weight loss, no RCT measuring pregnancy or live birth in PCOS, and no approval for this purpose anywhere.

Grading cuts both ways. A low grade does not prove something fails; it means nobody has shown it works. A high grade does not mean a treatment will work for you; it means the odds are known. Decisions should follow the gradient, with the strongest evidence tried first and the weakest reserved for research or honest experimentation under medical supervision.

Common myths about PCOS and fertility, corrected

“PCOS means you are infertile.” It does not. PCOS is a cause of subfertility, meaning reduced odds per month, not sterility. The NHS and Cleveland Clinic both state that most people with PCOS conceive, many with simple treatment and some without any.

“The cysts have to be removed before you can get pregnant.” The “cysts” are immature follicles, not growths. Surgery is a second-line option for a different reason (lowering androgen output), and removing follicles would reduce fertility, not improve it.

“You cannot have PCOS unless you are overweight.” Up to half of people with PCOS are in the normal weight range. Weight can worsen the hormonal picture but is neither a cause nor a requirement.

“Inositol works just as well as letrozole.” No trial has shown this. Inositol has modest evidence for metabolic markers and insufficient evidence for live birth. It is not a substitute for a prescribed ovulation-inducing medicine.

“Ozempic babies prove GLP-1 medicines are fertility drugs.” Unexpected pregnancies on these medicines have two plausible explanations with observational support: weight loss restoring ovulation in people who were not ovulating, and slower stomach emptying reducing absorption of oral contraceptives, a possibility noted in product labeling. Neither makes them fertility treatments. They are not approved for PCOS or for conception, labels advise against use in pregnancy, and anyone taking one who wants to conceive should raise timing with their prescriber rather than act alone.

“Years on the pill caused my PCOS or my infertility.” Hormonal contraception masks irregular cycles; it does not create them. Fertility returns to a person’s baseline within weeks of stopping, and that baseline was PCOS all along.

“If you ovulate sometimes, it is not PCOS.” One recognized phenotype includes regular cycles with excess androgen and polycystic ovaries. Irregular ovulation is common in PCOS but not universal.

Pregnancy with PCOS: risks to plan for, not to fear

Conception is the first milestone, not the finish line, and PCOS raises the odds of several pregnancy complications in ways that are well documented in observational studies and worth planning around.

Gestational diabetes is the most consistent finding, with pooled studies suggesting roughly a two- to three-fold increase compared with pregnancies in women without PCOS. The mechanism is the same insulin resistance that stalled ovulation, now meeting the insulin-resisting hormones of pregnancy. Many clinicians therefore offer glucose testing earlier than the usual 24–28 weeks. Pregnancy-induced high blood pressure and preeclampsia (high blood pressure with signs of organ stress after 20 weeks) are also more common, as are preterm birth and babies who are larger than average for their gestational age. Miscarriage rates appear higher in some cohorts, though how much of that is PCOS itself and how much reflects age, weight and the fertility treatments used remains debated; the Mayo Clinic lists it as an association rather than a certainty.

Two points temper the list. First, the absolute risks remain modest for most individuals; the majority of PCOS pregnancies are uncomplicated. Second, every one of these risks has an established monitoring pathway in routine antenatal care. Telling your maternity team about the diagnosis at the first visit is the single most useful thing you can do, because it changes which tests you are offered and when.

Looking beyond birth, PCOS is associated with a higher lifetime risk of type 2 diabetes, so a glucose check in the months after delivery and at intervals thereafter is standard advice. Some people with PCOS report difficulty establishing milk supply; the evidence is mixed and early support from a lactation specialist is reasonable. Preventive aspirin for those at elevated preeclampsia risk is a decision for the obstetric clinician, not for self-directed use.

When to see a doctor about PCOS and fertility

The conventional advice to try for a year before seeking help was written for people with regular cycles. If you have PCOS, or suspect it, the clock runs differently. Mainstream guidance supports booking an appointment sooner in any of these situations:

• Your cycles are consistently longer than 35 days, you have fewer than eight or nine periods a year, or you have gone three months or more without a period and are not pregnant.
• You are under 35 and have been trying for 12 months, or 35 or older and have been trying for six months, regardless of cycle pattern.
• You have a known PCOS diagnosis and are planning a pregnancy, because preconception assessment, partner testing and medicine review are best done before trying rather than after months of waiting.
• You are taking a GLP-1 medicine, metformin or any long-term prescription and want to conceive; timing and safety belong to your prescriber.

Certain symptoms need urgent, same-day attention rather than a routine appointment:

• During any fertility treatment: rapid abdominal swelling, severe pelvic or abdominal pain, persistent nausea or vomiting, shortness of breath, or passing much less urine than usual. These can signal ovarian hyperstimulation syndrome and need immediate assessment.
• Sudden, severe one-sided pelvic pain, with or without fainting, which can indicate ovarian torsion or an ectopic pregnancy.
• Very heavy bleeding (soaking through a pad or tampon every hour for several hours) or bleeding with dizziness.
• In pregnancy: severe headache, visual disturbance, sudden swelling of the face or hands, pain under the right ribs, or reduced fetal movements after 24 weeks.

Every option in this article, from lifestyle change to IVF, involves judgments about your specific history, phenotype, age and partner factors. A primary care physician or gynecologist can start the process; a reproductive endocrinologist takes over once medicines or procedures are on the table. Starting, stopping or adjusting any medicine, including one you already take for another condition, is a decision for the prescribing clinician.

Frequently asked questions

How do you get pregnant with PCOS naturally?

Some people with PCOS conceive without medicine, particularly those with milder phenotypes or who ovulate occasionally. Improving insulin sensitivity through regular exercise, sleep and, where relevant, modest weight loss can restore ovulation in a meaningful minority. Tracking ovulation by basal temperature or cervical mucus helps, but set a time limit and see a doctor if cycles stay irregular, since letrozole and other first-line options are safe and effective.

What are PCOS pregnancy chances compared with other women?

Over a reproductive lifetime, women with PCOS have family sizes similar to women without it, according to cohort studies. Month by month the odds are lower while ovulation is irregular, and treatment restores them toward the general-population figure of roughly one in five per cycle. In the largest tablet trial, about one in four women had a live birth within the treatment period on letrozole. Age and partner factors still shape individual odds.

How does PCOS ovulation induction work?

Ovulation induction uses medicines to help one follicle grow to maturity and release an egg. Letrozole and clomiphene do this indirectly by prompting the brain to release more follicle-stimulating hormone; injectable gonadotropins supply that hormone directly. Cycles are monitored with ultrasound and sometimes blood tests, and intercourse or insemination is timed to ovulation. A specialist sets the approach and adjusts it based on how your ovaries respond.

Is letrozole for PCOS better than Clomid?

On current evidence, yes for most people. A 750-woman randomized trial found higher ovulation and live birth rates with letrozole and fewer twins, and meta-analyses agree, so international guidelines now recommend letrozole first. Clomiphene (Clomid) still works well for many and remains a reasonable choice in some circumstances. Letrozole is used off-label for ovulation induction, and whether it suits you is a decision for your prescribing clinician.

Does metformin help you get pregnant if you have PCOS?

On its own, modestly at best; systematic reviews find small and uncertain effects on live birth. Metformin’s stronger role is alongside clomiphene in women who have not ovulated on clomiphene alone, where adding it improves ovulation and pregnancy rates. It is more likely to be considered in people with glucose intolerance or higher BMI. Metformin should only be used for PCOS under medical supervision, not as a do-it-yourself fertility aid.

Can you have PCOS and still have regular periods?

Yes. One of the four recognized PCOS phenotypes combines regular, ovulatory cycles with excess androgen and polycystic ovaries on ultrasound. People with this phenotype generally have fewer fertility difficulties than those with absent or very irregular periods, but they can still experience acne, excess hair growth and metabolic effects. Regular cycles alone do not rule the diagnosis in or out.

Do ovulation predictor kits work with PCOS?

Often poorly. Home kits detect the surge in luteinizing hormone that precedes ovulation, but many people with PCOS have persistently elevated baseline LH, which can produce positive results on days when no egg is released, or multiple false surges across a long cycle. Basal body temperature charting, cervical mucus observation or, during treatment, ultrasound monitoring tend to be more reliable. Ask your clinician which method fits your situation.

Does PCOS affect egg quality or just ovulation?

Mainly ovulation. The hallmark problem is that follicles stall before maturing, not that the eggs inside are defective. Ovarian reserve is typically high, which is why IVF often retrieves many eggs. Some studies suggest the hormonal environment of untreated PCOS may affect egg or embryo quality, and higher miscarriage rates in some cohorts are debated, but age remains the dominant influence on egg quality for everyone, PCOS or not.

Is inositol worth taking for PCOS fertility?

The evidence does not support it as a fertility treatment. Small, inconsistent trials suggest myo-inositol may improve some insulin and androgen markers, but there is no reliable data showing more live births, and the 2023 international guideline advises against considering it a treatment for conception outside research settings. It should never replace a prescribed ovulation-inducing medicine. If you want to try it, tell your clinician so it can be reviewed alongside everything else.

Will I need IVF if I have PCOS?

Most people will not. IVF is the final step on the ladder, reached only when lifestyle measures, tablets and injectable or surgical options have not led to pregnancy, or when there is another reason such as blocked tubes or a significant male factor. When IVF is needed, PCOS ovaries usually respond well, and a freeze-all strategy reduces hyperstimulation risk and improves live birth rates according to a large randomized trial.

References

• World Health Organization: Polycystic ovary syndrome fact sheet
• NHS: Polycystic ovary syndrome, treatment
• Cleveland Clinic: Polycystic ovary syndrome (PCOS)
• NIH (NICHD): Polycystic ovary syndrome (PCOS)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.